CPH signs Brazilian commercial agreement for distribution of cannabinoid-derived nutraceutical products
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH) has signed a binding Letter of Intent (LOI) with Brazil-based market-access and distribution service company Sin Solution, giving the leading supplier of cannabinoid-derived products a strategic foothold in the vast Latin American market.
As part of the agreement, Sin Solution will assist Creso with the commercialisation of its premium Swiss Vitamin nutraceuticals and its cannabinoid-derived nutraceutical products in Brazil – with sales targeting the privately insured middle class population of 60 million people with a potential market worth over $US800 million.
However, the take up of this product in Brazil remains to be seen. Investors considering this stock for their portfolio, should seek professional financial advice.
Sin Solution works with a number of high-profile commercial partners in Brazil and beyond, including giant Johnson & Johnson as well as GSK, Danone and Ache Do Brasil.
Through Sin Solution, CPH will be working with the following key marketing and distribution partners:
- Medicinal prescription and over-the-counter (OTC) pharmaceuticals and distribution company, Ache Do Brasil, who has more than 65,000 points of sales in Brazil. It promotes 316 brands and had 2015 net revenues of R$2.3 billion (AU$1 billion);
- Hypermarcas, the number one OTC pharmaceuticals company in Brazil has 15% market share and sales totalling R$1 billion (AU$420 million) in 2015, and;
- Biolab – among the top-10 biggest pharmaceutical companies in Brazil, with a field force of 1050 people. Biolab had sales of US$370 million in 2015, covering 250,000 medical professionals in Brazil and a market share of 2.13%.
In addition Sin Solution has direct access to more than 350,000 health professionals and over 200,000 direct patients.
The LatAm market is key for Creso Pharma, and consequently the ability to make a strong start in Brazil will put the company in prime position to launch its products in surrounding countries.
Sin Solution will act as a commercial partner for the commercialisation of Creso’s various Swiss Vitamin premium nutraceutical products as well as its cannabinoid-derived nutraceutical products.
The Swiss Vitamin premium nutraceutical products are based on INNutri’s unique delivery technology – with buccal absorption and high bioavailability – of premium vitamin mixes which can be used to support a variety of health needs. The range is targeted at the active middle-class working population.
This is the first step on a journey that will eventually see Creso launch its cannabinoid-derived nutraceutical products, which use the same innovative buccal delivery technology, to treat anxiety and stress.
As part of the process, Creso will register the premium Swiss Vitamin products in Brazil, followed by a launch in the second half of 2018 and the first sales of its products in the country.
“This agreement gives Creso entry into Latin America via a strategic partner in the continent’s largest economy, Brazil,” said Creso Pharma Group CEO and Co-Founder, Dr. Miri Halperin Wernli.
“Working with Sin Solution gives us access to further key commercial partners in the region and allows us to tap into a vast and fast-growing market, supporting the long-term growth of our business.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.